Michael Teufel, PhD (he/him/his)

Executive Director
Boehringer Ingelheim Pharmaceuticals Inc.
Ridgefield, Connecticut, United States

Michael Teufel has worked for over 15 years in the field of precision medicine and diagnostic development. Currently Michael holds the post of Executive Director Translational Medicine and Clinical Pharmacology at Boehringer Ingelheim where he has a global responsibility to create strategy and deliver a portfolio of precision medicine projects to improve clinical outcomes for patients in oncology programs.

Prior to joining Boehringer Ingelheim in 2020, Michael has worked at Sanofi Oncology and Bayer Pharma, where he led successful biomarker strategies leading to 4 sNDAs and 2 NDAs including successful approval of a CDx. Michael holds a PhD in Molecular Genetics from Germany.

Disclosure information not submitted.

Presentation(s):

• Paper 43 - BRIGIMADLIN VERSUS STANDARD-OF-CARE DOXORUBICIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA (DDLPS): BRIGHTLINE-1

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST